A28 Therapeutics, a clinical-stage biopharmaceutical company, has recently announced the completion of a comprehensive activity analysis for its AT-101 cancer drug candidate. This announcement was made during the J.P. Morgan Healthcare Conference. The analysis was conducted by GATC Health Corp, a leader in AI-driven drug discovery, validating the potential of AT-101 and providing A28 Therapeutics with a tool to optimize its clinical trial strategy. By assessing efficacy, safety and potential off-target effects, the analysis offers insights for reducing development risks, accelerating timelines and lowering costs.

“GATC has set the standard in leveraging advanced AI to objectively analyze drug compounds to provide valuable insight into key endpoints, like mechanisms of action and toxicity, while exposing non-obvious areas of risk,” explained Dr. Stanley Lewis, CEO of A28. “As an advisory board member since 2022, I have had direct access to the GATC team and understanding of the powerful toolset GATC uses to greatly de-risk research, development and financial decisions. This analysis provides an objective assessment of how our AT-101 drug candidate will perform in our next clinical trial.”

GATC’s Multiomics Advanced Technology (MAT) AI platform performed in-silico experiments to evaluate safety, efficacy and the side-effect profile for A28’s asset. The MAT platform generated predictions for primary pharmacokinetics, bioaccumulation, toxicology, ADME considerations, adverse event analysis, side effects, endpoint matching, efficacy ratios, mechanisms of action and immune response.

“GATC Health’s work with A28 demonstrates our ability to quickly provide deep insights and value into clinical-stage drug candidates utilizing the same technologies we employ for therapeutic discovery and early-stage development that can save years and tens of millions of dollars compared to traditional methods,” noted Jayson Uffens, co-founder and CTO. “This collaboration showcases our value to empower leaders and researchers in biotech to accelerate their pre-clinical development and de-risk their clinical and fundraising efforts.”